Sinopharm Group Co., Ltd., a leading player in the healthcare industry in China, boasts a low-risk ESG score of 18.5. Established in 2003, it is the primary distributor of pharmaceuticals and medical equipment in the country. Listed on the Hong Kong Stock Exchange in 2009, Sinopharm is a key subsidiary of China National Pharmaceutical Group. With pharmaceutical distribution forming the majority of its revenue, Sinopharm also has a significant presence in medical device distribution following its acquisition of China National Scientific Instruments and Materials in 2018. Catering to a wide range of customers, from hospitals to end-users, Sinopharm continues to grow and diversify its market reach.